Article citationsMore>>
S. A. Rosenberg, R. M. Sherry, K. E. Morton, W. J. Scharfman, J. C. Yang, S. L. Topalian, R. E. Royal, U. Kammula, N. P. Restifo, M. S. Hughes, D. Schwartzentruber, D. M. Berman, S. L. Schwarz, L. T. Ngo, S. A. Mavroukakis, D. E. White and S. M. Steinberg, “Tumor Progression Can Occur despite the Induction of Very High Levels of Self/Tumor Antigen-Specific CD8+ T Cells in Patients with Melanoma,” The Journal of Immunology, Vol. 175, No. 9, 2005, pp. 6169-6176.
has been cited by the following article:
-
TITLE:
Melanoma Immunotherapy: Overcoming Obstacles to Augment Anti-Tumor Immune Responses
AUTHORS:
Kristian M. Hargadon
KEYWORDS:
Melanoma; Tumor Immunotherapy; Dendritic Cell; Tumor Antigen; T Cell; Vaccine; Adoptive Transfer
JOURNAL NAME:
Journal of Cosmetics, Dermatological Sciences and Applications,
Vol.3 No.2A,
June
20,
2013
ABSTRACT:
Melanoma is the most aggressive form
of skin cancer and accounts for the vast majority of skin cancer-related
deaths. Its ability to metastasize quickly, often before diagnosis, makes this
cancer difficult to treat with traditional therapies. The identification of
anti-melanoma immune responses in patients and the discovery of tumor antigens
targeted by these immune responses have paved the way for immunotherapy as a
novel approach to treating this cancer. In this review, the major
immunotherapies targeting these melanoma tumor antigens are discussed. The
advantages and limitations of peptide-, protein-, and gene-based vaccination
maneuvers and adoptive cell transfer therapies are emphasized. Recent insights
into melanoma immune evasion strategies are also highlighted, with particular
focus on how our increasing knowledge of tumor/immune cell interactions is
driving the development of novel immunotherapeutic strategies for the treatment
of melanoma.
Related Articles:
-
Jai Dev Chandel, Nand Lal Singh
-
Ananda Prasad Panta, Ram Prasad Ghimire, Dinesh Panthi, Shankar Raj Pant
-
M. A. Helal, L. Marek-Crnjac, Ji-Huan He
-
Mohamed S. El Naschie
-
Xiting Chen